We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know
Read MoreHide Full Article
Gilead Sciences (GILD - Free Report) closed at $77.23 in the latest trading session, marking a -0.55% move from the prior day. This change lagged the S&P 500's daily gain of 0.28%. At the same time, the Dow added 0.08%, and the tech-heavy Nasdaq gained 0.61%.
Prior to today's trading, shares of the HIV and hepatitis C drugmaker had gained 1.44% over the past month. This has outpaced the Medical sector's loss of 0.13% and lagged the S&P 500's gain of 4.86% in that time.
Investors will be hoping for strength from Gilead Sciences as it approaches its next earnings release, which is expected to be August 3, 2023. On that day, Gilead Sciences is projected to report earnings of $1.62 per share, which would represent year-over-year growth of 2.53%. Meanwhile, our latest consensus estimate is calling for revenue of $6.43 billion, up 2.7% from the prior-year quarter.
For the full year, our Zacks Consensus Estimates are projecting earnings of $6.70 per share and revenue of $26.63 billion, which would represent changes of -7.71% and -2.38%, respectively, from the prior year.
It is also important to note the recent changes to analyst estimates for Gilead Sciences. These revisions help to show the ever-changing nature of near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.61% lower. Gilead Sciences is currently a Zacks Rank #3 (Hold).
Digging into valuation, Gilead Sciences currently has a Forward P/E ratio of 11.6. This valuation marks a discount compared to its industry's average Forward P/E of 18.51.
It is also worth noting that GILD currently has a PEG ratio of 0.9. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. The Medical - Biomedical and Genetics industry currently had an average PEG ratio of 1.91 as of yesterday's close.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 119, which puts it in the top 48% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow GILD in the coming trading sessions, be sure to utilize Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know
Gilead Sciences (GILD - Free Report) closed at $77.23 in the latest trading session, marking a -0.55% move from the prior day. This change lagged the S&P 500's daily gain of 0.28%. At the same time, the Dow added 0.08%, and the tech-heavy Nasdaq gained 0.61%.
Prior to today's trading, shares of the HIV and hepatitis C drugmaker had gained 1.44% over the past month. This has outpaced the Medical sector's loss of 0.13% and lagged the S&P 500's gain of 4.86% in that time.
Investors will be hoping for strength from Gilead Sciences as it approaches its next earnings release, which is expected to be August 3, 2023. On that day, Gilead Sciences is projected to report earnings of $1.62 per share, which would represent year-over-year growth of 2.53%. Meanwhile, our latest consensus estimate is calling for revenue of $6.43 billion, up 2.7% from the prior-year quarter.
For the full year, our Zacks Consensus Estimates are projecting earnings of $6.70 per share and revenue of $26.63 billion, which would represent changes of -7.71% and -2.38%, respectively, from the prior year.
It is also important to note the recent changes to analyst estimates for Gilead Sciences. These revisions help to show the ever-changing nature of near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.61% lower. Gilead Sciences is currently a Zacks Rank #3 (Hold).
Digging into valuation, Gilead Sciences currently has a Forward P/E ratio of 11.6. This valuation marks a discount compared to its industry's average Forward P/E of 18.51.
It is also worth noting that GILD currently has a PEG ratio of 0.9. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. The Medical - Biomedical and Genetics industry currently had an average PEG ratio of 1.91 as of yesterday's close.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 119, which puts it in the top 48% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow GILD in the coming trading sessions, be sure to utilize Zacks.com.